bioAffinity Technologies (BIAF) Projected to Post Quarterly Earnings on Monday

bioAffinity Technologies (NASDAQ:BIAF) is projected to post its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect bioAffinity Technologies to post earnings of ($2.70) per share and revenue of $1.5530 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 12:30 PM ET.

bioAffinity Technologies (NASDAQ:BIAF) last announced its earnings results on Saturday, March 14th. The company reported ($1.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.70) by $1.59. The company had revenue of $1.59 million for the quarter, compared to analysts’ expectations of $1.55 million. bioAffinity Technologies had a negative return on equity of 301.67% and a negative net margin of 241.93%.

bioAffinity Technologies Trading Down 15.6%

NASDAQ BIAF opened at $4.00 on Friday. The firm has a market capitalization of $18 million, a P/E ratio of -0.25 and a beta of 2.42. The business has a fifty day simple moving average of $1.59 and a 200 day simple moving average of $2.18. bioAffinity Technologies has a 12 month low of $0.69 and a 12 month high of $46.53. The company has a current ratio of 2.60, a quick ratio of 2.58 and a debt-to-equity ratio of 0.08.

Institutional Trading of bioAffinity Technologies

An institutional investor recently bought a new position in bioAffinity Technologies stock. Scientech Research LLC acquired a new position in bioAffinity Technologies, Inc. (NASDAQ:BIAF) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 16,583 shares of the company’s stock, valued at approximately $49,000. Scientech Research LLC owned 0.46% of bioAffinity Technologies as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 1.64% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of bioAffinity Technologies in a research note on Wednesday, January 21st. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Reduce”.

About bioAffinity Technologies

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.